Skip to main content

Table 4 Clinical outcomes data

From: Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry

Association between treatment modality and ventilator-free days aIRR (95% CI)
Steroids Reference
IL6-RAs
 VFD (model 1) 1.12 (0.88, 1.40)
 VFD (model 2 with highest FiO2 added) 1.13 (0.90, 1.42)
 VFD (model 2 with SOFA added) 1.12 (0.89, 1.40)
 Target trial design (model 3) 1.13 (0.87, 1.45)
Combination therapy
 VFD (model 1) 0.83 (0.60, 1.14)
 VFD (model 2 with highest FiO2 added) 0.88 (0.64, 1.20)
 VFD (model 2 with SOFA added) 0.77 (0.56, 1.06)
 Target trial design (model 3) 0.64 (0.34, 1.23)
Association between treatment modality and 28-day mortality aOR (95% CI)
Steroids N = 583 Reference
IL6-RAs
 28-day mortality (model 1) N = 168 0.68 (0.44; 1.07)
 Hospital morality (model 1) N = 170 0.68 (0.43, 1.09)
 28-day mortality (model 2) N = 170 0.7 (0.45, 1.08)
 Target trial design (model 3) N = 121 0.6 (0.35, 1.03)
Combination therapy
 28-day mortality (model 1) N = 104 1.07 (0.67, 1.70)
 Hospital morality (model 1) N = 101 1.23 (0.72, 2.11)
 28-day mortality (model 2) N = 101 1.21 (0.76, 1.93)
 Target trial design (model 3) N = 35 1.96 (0.90, 4.28)
  1. Missing data outcomes in sensitivity analysis (model 3): 4 patients had 28-day mortality status missing, and 15 patients had duration of iMV missing
  2. Adjusted incident rate ratio (aIRR) was used for VFD (> 1 is favorable for intervention), Adjusted odds ratio (aOR) was used for 28-day mortality (< 1 is favorable for intervention)
  3. aIRR adjusted incident rate ratio, aOR adjusted odds ratio, CI confidence interval, FiO2 fractional inspired oxygen concentration, IL6-RAs interleukin-6 receptor antagonists, SOFA Sequential Organ Failure Assessment, VFDs ventilation-free days